Company intelligence / Profile preview

Viken Oncology

Cambridge, Massachusetts, USA

Ownership: Private
Development stage: Other

Overview

Viken Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation precision medicines for cancer. The company leverages deep expertise in structural biology and protein engineering to target key drivers of tumor growth and immune evasion. Its lead program, VO-101, is a potent and selective small molecule inhibitor of USP7, currently being evaluated in Phase 1 clinical trials for patients with advanced solid tumors. Viken's approach focuses on high-value, well-validated targets that have historically been difficult to drug. The company is backed by leading life science investors and aims to transform the treatment landscape for patients with limited options.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Viken Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Viken Oncology.

Explore the full profile